Peter Salzmann, M.D.

Peter Salzmann, M.D.

Former Chief Executive OfficeratImmunovant· In proxies 2022–2025

Pay in FY2025Immunovant stock -47.1% the same year

Peter Salzmann, M.D. was paid $10.7M in FY2025 (Mar). Immunovant stock fell 47.1% that year.

Pay$100 in the stock at the end of FY21 → $18
Pay is from the Summary Compensation Table of each Immunovant proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ImmunovantPublic company · 4 yr
    • Former Chief Executive Officer2022 – Present · 4 yrStock in role +89%
  2. Corbus Pharmaceuticals HoldingsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Corbus Pharmaceuticals Holdings, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?